

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo	1	Y 1	Encorafenib/Binimetinib/Nivolu	35	16	4	3	2	2	1	01/06/2021	120	48
				2	Ipilimumab + Nivolumab	15	1	0	0	0	0			
						31	5	3	2	2	1			
Yes	EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		59	10	4	2	0	0	03/25/2016	241	92
						59	10	4	2	0	0			
No	S2015-MELAN, Stg I-II, 1cm v 2cm excision margins	1	E	Total Registrations		515	397	199	88	29	3	05/12/2022	160	64
						515	397	199	88	29	3			
	A091903-Melan, Resected Mucosal, Adj Nivo +/- Cabo	0	E	Total Registrations		1	0	0	0	0	0	11/01/2022	96	49
						1	0	0	0	0	0			
				1	Total Registrations	1	0	0	0	0	0	11/01/2022		
						1	0	0	0	0	0			
	EA6174-Merkel, Adjuvant Pembrolizumab vs Observation	1	E	Total Registrations		53	2	0	0	0	0	05/01/2019	308	108
						53	2	0	0	0	0			
	EA6192-Melan, Adv, Erly Discont of Antibdy Thrpy	0	E	Total Registrations		7	0	0	0	0	0	09/22/2021	126	56
						7	0	0	0	0	0			
				1	Total Registrations	8	0	0	0	0	0	09/22/2021		
						8	0	0	0	0	0			
	EA6194-Melan, Stage IIIB-D, Pembro +/- CMP-001	1	E	Total Registrations		3	3	3	3	2	0	12/22/2023		2
						3	3	3	3	2	0			